REVISED APPROVAL NOTICE

OFFICE FOR PROTECTION OF RESEARCH SUBJECTS
11000 Kinross Avenue, Suite 102
169407
www.oprs.ucla.edu

DATE: January 14, 2008

TO: John Pryor, M.A.
Principal Investigator

FROM: Nancy Levine, Ph.D.
Chair, North General Institutional Review Board

RE: UCLA IRB #G96-12-246-14
Approved by Full Committee Review
(Approval Period from 12/18/2007 **through** 11/14/2008)
Cooperative Institutional Research Program Triennial Survey of College Faculty [includes addendum: HERI faculty survey to be offered as a web-based survey; minor modification to the HERI faculty survey; revised administrative guidelines; revised research approval form]

Please be notified that the UCLA Institutional Review Board (UCLA IRB) has approved the above referenced research project involving the use of human subjects in research. The UCLA's Federalwide Assurance (FWA) with the Department of Health and Human Services, Office for Human Research Protections is FWA00004642.

PLEASE COMPLY WITH THE FOLLOWING CODICIL(S) IMPOSED BY THE IRB:

Codicil	Fulfilled Date
1. Please submit the renewed Certificate of Confidentiality for this study to the UCLA NGIRB once it has been obtained.	

Nancy E Levine

Approval Signature of the UCLA IRB Chair

PRINCIPLES TO BE FOLLOWED BY PRINCIPAL INVESTIGATORS:

As the Principal Investigator, you have ultimate responsibility for the conduct of the study, the ethical performance of the project, the protection of the rights and welfare of human subjects, and

strict adherence to any stipulations imposed by the UCLA IRB. You must abide by the following principles when conducting your research:

1. Perform the project by qualified personnel according to the approved protocol.
2. Do not implement changes in the approved protocol or consent form without prior UCLA IRB approval (except in a life-threatening emergency, if necessary to safeguard the well-being of human subjects.)
3. If written consent is required, obtain the legally effective written informed consent from human subjects or their legally responsible representative using only the currently approved UCLA-IRB stamped consent form.
4. Promptly report all undesirable and unintended, although not necessarily unexpected adverse reactions or events, that are the result of therapy or other intervention, within ten working days of occurrence. All fatal or life-threatening events must be reported to the UCLA IRB in writing within 2 working days after discovery.
5. In clinical medical research, any physician(s) caring for your research subjects must be fully aware of the protocol in which the subject is participating.
6. No subjects may be identified, contacted, recruited, or enrolled until the contract with the sponsor is finalized by the University.
7. Ensure that all individuals who will interact with subjects and/or have access to identifiable research data have completed the UCLA Protection of Human Research Subjects Certification.
8. Ensure that all individuals who will access subjects' medical records have completed the UCLA HIPAA Research Training Certification.
9. If non-UCLA sites or personnel are involved, follow all study-specific requirements and consent processes approved by the UCLA IRB.

FUNDING SOURCE(S):

According to the information provided in your application, the funding source(s) for this research project may include the following: N/A.